25.39
-0.93 (-3.53%)
| Previous Close | 26.32 |
| Open | 26.60 |
| Volume | 2,774,893 |
| Avg. Volume (3M) | 2,593,673 |
| Market Cap | 2,568,503,808 |
| Price / Sales | 37.71 |
| Price / Book | 2.47 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -1,596.87% |
| Diluted EPS (TTM) | -4.61 |
| Quarterly Revenue Growth (YOY) | 0.80% |
| Total Debt/Equity (MRQ) | 14.08% |
| Current Ratio (MRQ) | 8.81 |
| Operating Cash Flow (TTM) | -351.38 M |
| Levered Free Cash Flow (TTM) | -185.90 M |
| Return on Assets (TTM) | -19.05% |
| Return on Equity (TTM) | -38.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Beam Therapeutics Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.5 |
| Average | -0.30 |
|
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.22% |
| % Held by Institutions | 98.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mwg Management Ltd. | 30 Jun 2025 | 2,266,934 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 215.09%) | Buy |
| Median | 46.00 (81.17%) | |
| Low | 21.00 (Barclays, -17.29%) | Hold |
| Average | 49.00 (92.99%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 24.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Oct 2025 | 80.00 (215.08%) | Buy | 26.32 |
| 15 Sep 2025 | 80.00 (215.08%) | Buy | 21.28 | |
| JP Morgan | 09 Oct 2025 | 46.00 (81.17%) | Buy | 27.87 |
| Barclays | 06 Aug 2025 | 21.00 (-17.29%) | Hold | 18.30 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FMR LLC | - | 26.73 | -459 | -12,269 |
| Aggregate Net Quantity | -459 | |||
| Aggregate Net Value ($) | -12,269 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 26.73 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FMR LLC | 27 Oct 2025 | Sell (-) | 459 | 26.73 | 12,269 |
| Date | Type | Details |
|---|---|---|
| 25 Aug 2025 | Announcement | Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences |
| 14 Aug 2025 | Announcement | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |